scispace - formally typeset
Open AccessJournal ArticleDOI

CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma

Reads0
Chats0
TLDR
It is demonstrated for the first time that elevated CXCL13 concentration in cerebrospinal fluid (CSF) is prognostic and that CXC chemokine ligand and IL-10 mediate chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.
About
This article is published in Blood.The article was published on 2013-06-06 and is currently open access. It has received 178 citations till now. The article focuses on the topics: Lymphoma & CXCL13.

read more

Citations
More filters
Journal ArticleDOI

Lyme neuroborreliosis—epidemiology, diagnosis and management

TL;DR: There is evidence that patients with post-treatment Lyme disease syndrome do not have ongoing B. burgdorferi infection and, thus, do not benefit from additional antibiotic therapy, and most patients who receive this diagnosis have other illnesses.
Journal ArticleDOI

CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

TL;DR: The complex networks of cellular interactions involving tumoral CXCL13 and CXCR5 integrate to promote cancer cell autonomous and non-autonomous responses, highlighting the relevance of autocrine and paracrine interactions in dictating the cancer phenotype.
Journal ArticleDOI

How I treat CNS lymphomas

TL;DR: The goal is to provide an overview of current knowledge regarding the pathogenesis of CNS lymphomas and to highlight promising strategies that the authors believe to be most effective in establishing diagnosis, staging, and therapeutic management.
References
More filters
Journal ArticleDOI

Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system

TL;DR: CSF miRNAs are potentially useful tools as novel noninvasive biomarker for the diagnosis of PCNSL and combined miRNA analyses resulted in an increased diagnostic accuracy and a remarkable stability of mi RNAs in the CSF.
Journal Article

Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.

TL;DR: It is demonstrated by phosphoprotein immunoblotting analysis and electrophoretic mobility shift analysis that piceatannol and AG490 inhibit the constitutive activity of STAT3 in 2F7 and U266, respectively, and are a novel class of chemotherapeutic sensitizing agents capable of reversing the drug-resistant phenotype of cytokine-dependent tumor cells.
Journal ArticleDOI

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

TL;DR: TheChemokine CXCL13 may play a major role in recruitment of B cells and T-cell subsets expressing the chemokine receptor CXCR5 to the CNS in multiple sclerosis (MS), and may be a useful biomarker for treatment effects in MS.
Journal ArticleDOI

Expression of B-cell–attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma

TL;DR: Investigation of the expression of B cell-attracting chemokine 1 (BCA-1, CXCL13) in primary central nervous system lymphoma found it to influence tumor development and localization to CNS, suggesting that vascular endothelial BCA-1 expression may be consequent to transcytosis.
Journal ArticleDOI

6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma.

TL;DR: In this paper, the loss of heterozygosity of 6q loci in non-Hodgkin's lymphoma (NHL) showed two regions of minimal molecular deletion (RMD), an RMD1 encompassing 6q25-27 and an RMMD2 at 6q21-23, and the deletions spanned both RCD1 and RCD3.
Related Papers (5)